Attention:
Card image cap

A Look Inside a DEA Investigation and Prosecution of Opioid Prescribing and the Controlled Substances Act: The Opioid Odyssey and the Aftermath of Bad Decisions


Level: Intermediate
Runtime: 63 minutes
Recorded Date: May 25, 2022
Click here to share this program
Printer-Friendly Version
Closed Caption

Agenda

  • Case study: United Sates vs. C. Mark Capistrano, ET AL.
  • Expert review and Opinion
  • Outcomes and additional actions
  • Treatment and Intervention
  • Future considerations


Runtime: 1 hour, 3 minutes
Recorded: May 25, 2022


For NY - Difficulty Level: For both newly admitted & experienced attorneys

For NY - Difficulty Level: Both newly admitted and experienced attorneys

Description

In this session, panelists will provide an overview of DEA Diversion and CSA sanctions, along with a case study that will reveal the ramifications of prescribing controlled substances outside the scope of professional practice, federal law as it relates to physicians and pharmacies dispensing controlled substances outside the usual course of medical practice, and Medication Assisted Recovery as an evidenced based intervention that can be used in conjunction with community based interventions to reduce many of the consequences brought on by the opioid epidemic.



This program was recorded on May 25th, 2022.

Provided By

American Bar Association
Card image cap

Panelists

Card image cap

Adam Wyatt

Clinic Director of Opioid Treatment Program
Acadia Healthcare

Adam Wyatt is the Clinic Director of Opioid Treatment Program in Oklahoma City.
With 8 Years of experience working in Mental Health and Substance Abuse, Adam is proudly providing services to those in in search of recovery. Adam also has experience in Leadership, Community outreach, and Coaching.

Card image cap

Gregory M. Fliszar

Partner
Cozen O'Connor


Greg focuses his practice on health law and handles a variety of health law litigation and regulatory and compliance matters for a number of different types of health care providers, including hospitals, hospices, mental health providers and physician groups. He has significant experience with HIPAA and privacy issues and has counseled insurance company clients on understanding their obligations under the Medicare Secondary Payer Act. He returned to Cozen O'Connor after briefly serving as Associate General Counsel to Universal Health Services.
Greg has written and spoken about a number of health law issues, including HIPAA and privacy/confidentiality issues, as well as the Medicare Secondary Payer Act. He is the chair of the Substance Abuse Disorders and Mental Health Interest Group of the ABA's Health Law Section.
Greg was named a Pennsylvania Super Lawyer Rising Star for health care in 2005, 2006, 2010 and 2011. Prior to attending law school, Greg worked as a clinical psychologist in inpatient and outpatient settings and was a clinical instructor of psychiatry at the MCP-Hahnemann School of Medicine in Philadelphia. Greg is currently the co-chair of the American Bar Association's Joint Opioid Task Force. In addition, he is a former member of the boards of directors of the AIDS Law Project of Pennsylvania and ALFA, an HIV/AIDS service organization in Hickory, N.C.
Greg earned his B.A. from the University of Notre Dame. He earned a master's degree and a Ph.D. in clinical psychology from Texas Tech University. He earned his law degree, summa cum laude, from the University of Pittsburgh School of Law, where he was research editor of the University of Pittsburgh Law Review, a member of the Order of the Coif, recipient of the David Stahl Memorial Award and earned a Certificate of Advanced Study in Health Law.


Card image cap

Similar Courses

Card image cap
64 minutes
"I Am Not a Cat" Proceedings in a Virtual World
Besides becoming a pop-culture catchphrase, how has the shift to a virtual environment impacted proceedings over the last year, and what changes do you believe are here to stay? Our panel of experts will examine some of the greatest challenges, faux pas, and successes in virtual proceedings over the course of this transformative time.

Women, Influence & Power in Law Conference

$65

Add to Cart
Card image cap
74 minutes
Anatomy of a Pharmaceutical Bankruptcy Case
This panel will present a primer on the U.S. pharmaceutical industry, focusing on the typical capital structures of pharmaceutical/development companies versus in-pipeline companies. The panelists will examine the factors leading to the recent surge in pharmaceutical bankruptcy cases and their outcomes/resolutions, as well as ? 363 sales of pharmaceutical companies’ assets and restructurings. Opiate bankruptcy cases such as Purdue and Mallinckrodt will be highlighted, as will ancillary issues that arise in pharmaceutical bankruptcy cases, such as product recalls, regulatory issues (such as with the FDA) and IP licensing issues.

American Bankruptcy Institute

$95

Add to Cart
Card image cap
59 minutes
Attorney Fee Bifurcation
A bifurcated fee arrangement involves splitting the consumer chapter 7 engagement into pre-petition and post-petition fee arrangements that require little or no money down for the work required to finish the case. In several jurisdictions across the nation, however, bifurcated fee arrangements in chapter 7 cases are being challenged. This panel will review the complex issues related to these fee arrangements.

American Bankruptcy Institute

$75

Add to Cart
Card image cap
76 minutes
But I’m Afraid of Needles: The Sale of Health Care Assets
This panel will discuss various issues and challenges accompanying sales of health care assets, including factors to consider in determining whether or not a sale is the best alternative. Such factors include the role of regulatory authorities, political challenges, reimbursement issues, issues related to urban vs. rural facilities, the evolution of the health care business, and best practices in navigating such challenges.

American Bankruptcy Institute

$95

Add to Cart
Previous Next